ACAD
18.26
+0.71
+4.05%
AEMD
4.84
-0.56
-10.37%
APRI
1.14
-0.03
-2.56%
ARNA
1.52
+0.05
+3.40%
ATEC
0.205
-0.004
-1.914%
CNAT
1.73
+0.08
+4.85%
CRXM
0.2
-0.03
-12.28%
CYTX
0.133
0.00
0.00%
DXCM
56.12
-0.13
-0.23%
GNMK
4.78
-0.26
-5.16%
HALO
7.54
+0.11
+1.48%
ILMN
142.72
+4.26
+3.08%
INNV
0.06
+0.01
+20.00%
INO
6.27
+0.08
+1.29%
ISCO
2.44
-0.17
-6.51%
ISIS
57.56
0.00
0.00%
LGND
85.97
+0.18
+0.21%
LPTN
0.156
+0.00
+0.0644%
MBVX
0.53
0.00
+0.23%
MEIP
1.04
-0.02
-1.89%
MNOV
4.19
-0.03
-0.71%
MRTX
20.11
+0.72
+3.71%
MSTX
0.256
+0.021
+8.7197%
NBIX
36.04
+0.67
+1.89%
NUVA
39.12
-2.7
-6.46%
ONCS
1.68
+0.17
+11.26%
ONVO
1.89
-0.04
-2.07%
OREX
1.64
-0.01
-0.61%
OTIC
14.33
+0.37
+2.65%
QDEL
14.99
-0.29
-1.90%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.01
-0.17%
RMD
57.88
+0.76
+1.33%
SCIE
0.001
+0.00
+14.2857%
SPHS
1.58
+0.01
+0.64%
SRNE
5.52
+0.63
+12.88%
TROV
3.76
-0.15
-3.84%
VICL
0.305
-0.015
-4.6904%
VOLC
18
0.00
0.00%
ZGNX
9.79
+0.27
+2.84%
ACAD
18.26
+0.71
+4.05%
AEMD
4.84
-0.56
-10.37%
APRI
1.14
-0.03
-2.56%
ARNA
1.52
+0.05
+3.40%
ATEC
0.205
-0.004
-1.914%
CNAT
1.73
+0.08
+4.85%
CRXM
0.2
-0.03
-12.28%
CYTX
0.133
0.00
0.00%
DXCM
56.12
-0.13
-0.23%
GNMK
4.78
-0.26
-5.16%
HALO
7.54
+0.11
+1.48%
ILMN
142.72
+4.26
+3.08%
INNV
0.06
+0.01
+20.00%
INO
6.27
+0.08
+1.29%
ISCO
2.44
-0.17
-6.51%
ISIS
57.56
0.00
0.00%
LGND
85.97
+0.18
+0.21%
LPTN
0.156
+0.00
+0.0644%
MBVX
0.53
0.00
+0.23%
MEIP
1.04
-0.02
-1.89%
MNOV
4.19
-0.03
-0.71%
MRTX
20.11
+0.72
+3.71%
MSTX
0.256
+0.021
+8.7197%
NBIX
36.04
+0.67
+1.89%
NUVA
39.12
-2.7
-6.46%
ONCS
1.68
+0.17
+11.26%
ONVO
1.89
-0.04
-2.07%
OREX
1.64
-0.01
-0.61%
OTIC
14.33
+0.37
+2.65%
QDEL
14.99
-0.29
-1.90%
RCPT
231.96
0.00
0.00%
RGLS
5.84
-0.01
-0.17%
RMD
57.88
+0.76
+1.33%
SCIE
0.001
+0.00
+14.2857%
SPHS
1.58
+0.01
+0.64%
SRNE
5.52
+0.63
+12.88%
TROV
3.76
-0.15
-3.84%
VICL
0.305
-0.015
-4.6904%
VOLC
18
0.00
0.00%
ZGNX
9.79
+0.27
+2.84%
Home » Archive by Category

Syndication

ENTRY LEVEL SALES / Perfect Start for Recent Grads – $40,000-$80,000y (San Diego)

January 19, 2016 – 12:23 pm

Fast growing web marketing company that provides websites, social media, SEO and paid search solutions to the businesses throughout the country is seeking a Sales Representative to contact prospective clients and schedule online appointments for a de […

Senior Recruiter/Recruiter – SimulStat Inc. – San Diego, CA

January 19, 2016 – 12:22 pm

Prior pharmaceutical and biotechnology recruiting experience. Recruit nationally for major Pharmaceutical, Biotechnology and Clinical Research Organizations…
From Postings.com – 19 Jan 2016 19:22:05 GMT
– View all San Diego jobs

Data Scientist Wanted

January 19, 2016 – 11:59 am

Seeking a data scientist to join an expanding artificial intelligence startup in San Diego.
Contact
show contact info
to apply
Who Are We
At Gofer, we are building a Siri-like assistant that automates critical business tasks. The software sits on…

Production Team Lead (Vista, Ca)

January 19, 2016 – 11:39 am

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry.
Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as ac […

Technical Writer (Contract) – The Mice Groups – San Diego, CA

January 19, 2016 – 11:15 am

We provide professional technology staffing solutions to the most respected companies in a variety of industries, including Finance and Banking, Software…
From Indeed – 19 Jan 2016 18:15:26 GMT
– View all San Diego jobs

Technical Writer (Contract) – The Mice Groups – San Diego, CA

January 19, 2016 – 11:15 am

We provide professional technology staffing solutions to the most respected companies in a variety of industries, including Finance and Banking, Software…
From Indeed – 19 Jan 2016 18:15:26 GMT
– View all San Diego jobs

Research Assistant/Associate – Analytical and Process Development (Sorrento Valley)

January 19, 2016 – 11:02 am

Description:
We are a leading metabolic engineering company in San Diego, CA, focused on the use of gene editing tools to construct commercially valuable strains of microorganisms, to produce and deliver high-value, performance-focused and sustainab […

Marketing/Business Development Specialist (San Diego)

January 19, 2016 – 9:39 am

Marketing/Business Development Specialist
San Diego Biotech firm located in Mira Mesa is seeking an energetic, intelligent, and resourceful individual to join our Marketing/Business Development Team.
The successful candidate will be an engaging sel […

Serene Medical Announces Completed Enrollment of their First Clinical Trial

January 19, 2016 – 7:23 am

Evaluating the First-to-Market Neurotoxin-Free and Long-Lasting Procedure Developed to Treat Glabellar Lines

SAN RAMON, Calif., Jan. 19, 2016 /PRNewswire/ — Serene Medical Pty. Ltd., a medical device pioneer in RF technology, has recently completed enrollment of its prospective multi-center trial evaluating the effectiveness of the Serene RF System. The Serene clinical trial, which began in February 2015 includes five sites in the U.S. and two sites in Australia. This year long study is designed to evaluate the Serene RF System’s ability to effectively improve the appearance of dynamic moderate to severe glabellar lines and sustain long-term aesthetic results. Throughout the trial over 75 patients will serve to validate aesthetic benefits and support the subsequent launch of the Serene RF System which is planned for release in late 2016.

“The excitement and positive responses that have been received to-date from physician partners and their patient base is proof that the aesthetic market is ready for an alternative protocol to what is currently available,” says Bankim Mehta, CEO and President of Serene Medical. “With the complete enrollment of the study of the Serene RF System, we look forward to demonstrating how this device, using novel combinations of bi-polar radiofrequency and nerve stimulation technologies, provide long-lasting and toxin free results.”

Trevor Moody, Serene Board Member and Managing Director at M.H. Carnegie & Co., with a 25 year career commercializing and funding innovative medical devices, said that the Serene RF system represents an exciting and revolutionary approach to the treatment for glabellar lines. “Physicians and patients will soon benefit from this important new technology.”  

Serene RF System
Serene Medical has received clearance from the Food and Drug Administration (FDA) to market its Serene Radio Frequency System. Efforts to obtain the CE mark for European commercialization are currently under way. The Serene RF System utilizes a novel, patent protected, radiofrequency technology for locating and treating nerves that cause dynamic wrinkles. The Serene System provides patients immediate visible results and a natural looking, long-duration effect compared to neurotoxin injections. The multicenter study is currently being conducted to document clinical outcomes.

About Serene Medical
Serene Medical is a privately held medical device company with proprietary technology for selectively targeting overactive motor nerves. The first application of Serene technology is planned for the aesthetic market while other therapeutic applications are being explored. Founded in 2010, Serene Medical Pty. Ltd. is a pioneer of RF technology in both the US and Australia and is overseen by a strong board of seasoned entrepreneurs including Bankim Mehta, President and CEO, Trevor Moody, representing M.H. Carnegie and Co. and Elaine Stead, Ph.D. of Blue Sky Venture Capital. Serene holds six issued US device and method patents. Serene continues to file new patent applications maintaining its strong IP position as it commercializes the technology.

For additional information on Serene Medical, please visit www.serenemedical.com

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS 
This press release may contain projections or other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release, including any statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time. New risks emerge from time to time. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995.

Logo – http://photos.prnewswire.com/prnh/20160118/323269LOGO

SOURCE Serene Medical

Abide Therapeutics Appoints Richard N. Kender to Board of Directors

January 19, 2016 – 6:00 am

SAN DIEGO, Jan. 19, 2016 /PRNewswire/ — Abide Therapeutics announced today the appointment of Richard N. Kender to its Board of Directors. Kender is a consultant to biotechnology companies in the areas of partnerships and licensing and mergers and acquisitions. He was previously Senior Vice President of Business Development and Corporate Licensing at Merck & Co., Inc. During his career at Merck, Kender was actively involved in more than 100 transactions, including a number that greatly influenced the course of the company. Kender also held positions with Merck in corporate finance, as well as in financial support of the domestic and international commercial and manufacturing divisions.

“With his deep expertise in multiple facets of the pharmaceutical business, Rich will be an asset to Abide’s Board of Directors,” said Alan Ezekowitz, MBChB, D.Phil., President and CEO of Abide Therapeutics. “We are confident that Rich will contribute to shaping our corporate and commercial efforts to most effectively advance our clinical pipeline of first-in-class therapeutics.”

In July 2015, Abide began enrollment in its first clinical study, a Phase 1a clinical study of ABX-1431, an investigational endocannabinoid system modulator with potential indications in symptomatic improvement in multiple sclerosis, neuroinflammation, acute and chronic pain, agitation in Alzheimer’s disease, and pain in irritable bowel syndrome.

“Abide Therapeutics is leading the development of a novel and relatively unexplored class of therapeutics targeting serine hydrolases,” said Kender. “I look forward to joining the Board of Directors and helping Abide take advantage of their unique position to develop novel therapies to treat a number of unmet medical needs.”

Kender currently serves on the boards of INC Research (INCR), a leading global contract research organization; Seres Therapeutics, developing microbiome-based therapeutics; and POXEL SA, developing drugs to treat type 2 diabetes. Kender obtained his B.S. in accounting from Villanova University and his MBA from Fairleigh Dickinson University.

About Serine Hydrolases

The large family of serine hydrolases are validated but largely underexplored as drug targets. These enzymes play a key regulatory role in human physiological processes, such as regulating CNS signaling, digestion, metabolism, inflammation, blood clotting, and life cycle of viruses and pathogens. Thus, the ability to target serine hydrolases has broad therapeutic applications. The proprietary Abide technology platform provides a unique highly selective small molecule collection that specifically targets the common catalytic site of serine hydrolases. The technology provides a rapid and effective method for target identification and validation. 

About Abide Therapeutics

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Serine hydrolases play important regulatory roles in human physiology and disease. Abide has created a proprietary platform, based on technology developed at The Scripps Research Institute by Professors Ben Cravatt and Dale Boger, that specifically targets serine hydrolases with selective small molecules. The ability to target and modulate serine hydrolases has potential to develop new medicines in many therapeutic areas. Abide is located in San Diego. To learn more, visit www.abidetx.com

 

SOURCE Abide Therapeutics